Blog
About

13
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Age-Related Changes in Gut Microbiota Alter Phenotype of Muscularis Macrophages and Disrupt Gastrointestinal Motility

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Macrophages are classified as proinflammatory M1 (classically activated) or anti-inflammatory M2 (alternatively activated), 1 but binary classification fails to distinguish macrophage expression profiles. 2 Tissue resident muscularis macrophages (MMs) in the gut muscularis externa modulate gut homeostasis including neuromuscular function.3, 4 Through neuroimmune cross-talk, MMs may sense cues in the microenvironment from the microbiota or extrinsic sympathetic neurons and relay this information to enteric neurons.3, 4 We showed that aging shifts the phenotype of MMs from an M2 to an M1 polarization state, which is associated with chronic, low-grade inflammation in the enteric nervous system and delayed intestinal transit. 5 The objective of this study was to evaluate whether alterations in gut microbiota contribute to age-related changes in MMs and gastrointestinal dysmotility. To determine the effect of microbiota on MM phenotype, germ-free (GF) mice were colonized by co-housing with young (age, 2 mo) or old (age, 24 mo) mice (Figure 1 A). 6 After 4 weeks, MMs were sorted from the colonized GF mice, termed GFyoung or GFold, and analyzed for RNA expression. MMs from GFold mice showed decreased expression of anti-inflammatory M2 markers, particularly found in inflammatory zone 1, C-type lectin domain family 10 member A, and interleukin 10 (Figure 1 B), and increased expression of the proinflammatory M1 marker tumor necrosis factor α (TNFα) (Figure 1 C). Increased TNFα also was detected in protein extract of muscularis externa (Figure 1 D), which mirrors recent studies showing higher TNFα levels in plasma 6 and in ileum 7 of GF mice colonized with old mice microbiota. We also found increased leukocyte infiltration in the muscularis of GFold mice (Figure 1 E), suggesting that factors in the old microbiota drives inflammation. Figure 1 Microbiota from old mice alters macrophage phenotype and causes delayed intestinal transit. (A) GF mice were co-housed with either young or old mice for 1 month before expression analysis was performed on sorted MMs. MMs from GFold mice showed reduced expression of anti-inflammatory M2 markers, particularly found in inflammatory zone 1 (FIZZ1), C-type lectin domain family 10 member A (CLEC10A), and interleukin 10 (IL10), (B) which were statistically significant, and (C) statistically significantly increased expression of TNFα compared with GFyoung. This change in phenotype corresponded to (D) increased levels of TNFα and (E) increased infiltration of CD45+ leukocytes in muscularis. Data are representative of 3 independent experiments. (F) After antibiotic (Abx) treatment, FMT was performed on old mice with young or old stool. Whole-gut transit times (WGTTs) were measured at baseline (pre-Abx), before FMT (post-Abx), and after FMT. (G) A statistically significant reduction in transit times was observed in mice after FMT with young stool (FTyoung) compared with before and after Abx treatment, which was not observed in mice transplanted with old stool (FTold). Data are combined from 2 independent experiments. n ≥ 5 for each group. *P < .05, **P < .01, ***P < .005 by t test or 1-way analysis of variance, with the Bonferroni multiple comparisons test. Data are represented as means ± SD. Next, we tested whether age-dependent differences in the microbiota influence gastrointestinal (GI) motility. Old mice were pretreated with an antibiotic cocktail and then fecal microbiota transplantation (FMT) was performed by gavage of young or old mice stool. Whole-gut transit times were measured at baseline (pre-antibiotic treatment), before FMT (after antibiotic treatment), and after FMT (Figure 1 F). FMT with young but not old stool resulted in a significant reduction in whole-gut transit times (Figure 1 G). This suggests that in addition to altering MM phenotype, age-dependent factors in the microbiota affect gut motility. Microbiota-mediated loss of barrier function is implicated in age-associated intestinal inflammation in Drosophila and mice,6, 8, 9 and appears to be TNFα-dependent. 6 This suggests that microbial factors trigger an inflammatory response that presages disruption of barrier function. Bile acids (BAs) are a logical candidate because they are metabolized by the microbiota and known to modulate the immune response by signaling through host receptors. 10 By using targeted metabolomics, we found increased deconjugated BAs in fecal pellets from old mice (Supplementary Figure 1 A). Deconjugated primary BAs were increased in particular, showing a 20-fold increase compared with stool from young mice (Supplementary Figure 1 B). Similarly, stool from GFold mice contained increased deconjugated primary BAs, suggesting that the MM phenotype in our colonized GF mice is mediated through BAs (Supplementary Figure 1 C). Takeda G-protein coupled receptor 5 (TGR5), also known as G-protein–coupled bile acid receptor 1, has been detected on human and mouse small intestinal macrophages3, 11 by RNA sequencing and can modulate the macrophage immune response. 12 Tgr5 is differentially activated by various bile acids,12, 13 with conjugated BAs leading to greater affinity and activation than deconjugated equivalents.12, 14 We speculated that increased conjugated BAs in stool of young mice maintain an anti-inflammatory phenotype in MMs through TGR5 signaling. To test this, we performed immunophenotyping of MMs from TGR5 knockout mice (tgr5-ko) and wild-type littermates (tgr5-wt) by flow cytometry. MMs from tgr5-ko mice showed decreased surface expression of the M2 marker CD206 (Figure 2 A), suggesting that TGR5 deficiency results in loss of M2 phenotype. Figure 2 TGR5 deficiency in MMs causes loss of M2 phenotype and delayed intestinal transit. (A) MMs from tgr5-ko mice showed statistically significantly decreased surface expression of M2 markers CD206 compared with tgr5-wt based on the mean fluorescence intensity (MFI) normalized to isotype controls. (B) Bone marrow chimeras were generated by injecting bone marrow from tgr5-ko or tgr5-wt mice into lethally irradiated tgr5-wt mice. Data are combined from 2 independent experiments. (C) Mice transplanted with bone marrow from tgr5-ko mice (KO→WT) showed statistically significantly delayed intestinal transit compared with those transplanted with wild-type bone marrow (WT→WT). Data are representative of 2 independent whole-gut transit time experiments. (D) Proposed model by which age-dependent changes in microbiota cause a shift from conjugated to deconjugated BAs, resulting in a loss of M2 phenotype in MMs and delayed intestinal transit. n ≥ 9 for each group. *P < .05 by t test. Tgr5-ko mice have been reported to show delayed intestinal transit. 15 Because TGR5 is expressed in multiple cell types, 15 we asked whether altered MM phenotype caused by TGR5 deficiency contributes to disrupted intestinal motility. We generated bone marrow chimeras by transplanting bone marrow from tgr5-ko or tgr5-wt mice into lethally irradiated tgr5-wt mice (Figure 2 B). KO→WT chimeric mice showed delayed intestinal transit compared with WT→WT (Figure 2 C), suggesting that decreased BA signaling through TGR5 in MMs contributes to age-related disruption in motility. Based on our results, we propose the following model for how aging affects GI motility (Figure 2 D). Age-dependent alterations in gut microbiota cause a shift from conjugated to deconjugated BAs. This change in the conjugation status results in diminished TGR5 signaling on MMs, contributing to loss of anti-inflammatory phenotype and delayed intestinal transit. Our findings also offer several mechanistic and potential therapeutic interventions that might be used in treating age-related GI motility disorder. Further studies in human beings will be necessary to determine the clinical relevance.

          Related collections

          Author and article information

          Contributors
          Journal
          Cell Mol Gastroenterol Hepatol
          Cell Mol Gastroenterol Hepatol
          Cellular and Molecular Gastroenterology and Hepatology
          Elsevier
          2352-345X
          2019
          17 September 2018
          : 7
          : 1
          : 243-245.e2
          Affiliations
          Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University, Stanford, California
          Author notes
          Article
          S2352-345X(18)30120-6
          10.1016/j.jcmgh.2018.09.001
          6305843
          © 2019 The Authors

          This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

          Categories
          Research Letter

          Comments

          Comment on this article